Century Therapeutics, Inc.

NASDAQ:IPSC

Biotechnology

Healthcare
$1.38 +0.48%

+$0.01 today

Market cap
$250.60M
Beta
1.57
P/E (TTM)
-1.8
EPS (TTM)
-$1.25
52W Low $0.44High $3.04

Volume 1.14M

Average 1.12M

IPSC Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Century Therapeutics, Inc.NASDAQ: IPSC

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $3M, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $29.86M.

Context

  • Cost of revenue amounted to 12.0% of revenue in FY2025, up 12.0 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $3M or moves back toward the trailing-twelve-month quarterly average of $7.47M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3M— QoQ
Last fiscal yearDec 2025
$13.1M— YoY
LTMMar 2026
$29.86M— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
13.1M USD
Year-over-year change
—
4-year CAGR
+30.0%

Cost of Revenue vs competitors

How IPSC compares with its peers on the latest reported figures

  • IPSC's LTM Mar 2026 cost of revenue of $29.86M is the highest of the 8 companies compared; the peer median is $180.63K.
IPSC Competitors Peer median
Cost of Revenue for IPSC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IPSCCentury Therapeutics, Inc.LTM Mar 2026$29.86M ———
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$6.01M +9.4%+4.5%4.0%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$1.54M +977.1%+54.6%460.9%
OSTXOS Therapies IncorporatedLTM Mar 2026$362.39K +17280.8%+666.9%—
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$180.63K +300.0%—12.8%
CUECue Biopharma, Inc.LTM Mar 2026$79K ——0.2%
EQEquillium, Inc.LTM Mar 2026$79K ———
TELOTelomir Pharmaceuticals, Inc. Common StockLTM Mar 2026$0 ———
Peer median (excluding IPSC) $180.63K+638.6%+54.6%8.4%

Competitors are the stored peer set for IPSC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue05.2M2.24M6.59M109.16M
Cost of Revenue4.58M00013.1M
Gross Profit(4.58M)5.2M2.24M6.59M96.06M
Gross Margin—100.0%100.0%100.0%88.0%
Research & Development75.65M97.17M92.71M107.24M95.67M
Selling, General & Admin14.65M31.86M34.71M33.16M24M
Operating Expenses90.3M139.03M148.78M144.73M111.1M
Depreciation & Amortization4.58M8.44M13.04M13.3M13.1M
EBITDA(89.92M)(121.2M)(121.21M)(111.47M)3.45M
EBITDA Margin—-2331.2%-5423.2%-1691.8%3.2%
Operating Income(94.88M)(133.83M)(146.55M)(138.14M)(15.04M)
Operating Margin—-2574.2%-6556.9%-2096.5%-13.8%
Interest Income898K2.99M12.68M13.01M7.35M
Interest Expense1.28M0540K00
Other Income / Expenses(898K)2.99M11.75M13.36M5.39M
Income Before Tax(95.78M)(130.84M)(134.79M)(124.78M)(9.65M)
Pre-Tax Margin—-2516.7%-6031.0%-1893.7%-8.8%
Income Tax Expense43K91K1.88M1.79M(68K)
Net Income(95.82M)(130.93M)(136.67M)(126.57M)(9.58M)
Net Margin—-2518.4%-6115.1%-1920.9%-8.8%
EPS (Basic)(1.74)(2.27)(2.30)(1.61)(0.11)
EPS (Diluted)(1.74)(2.27)(2.30)(1.61)(0.11)
Weighted Avg Shares55.01M57.76M59.31M78.65M86.56M
Weighted Avg Shares (Diluted)55.01M57.76M59.31M78.65M86.56M

Century Therapeutics, Inc.

NASDAQ:IPSC

Intrinsic Alpha fair value

Locked

Current Price

$1.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.